ATH3G10 / Athera - LARVOL DELTA

Phosphorylcholine Monoclonal Antibody Therapy Decreases Intraplaque Angiogenesis and Intraplaque Hemorrhage in Murine Vein Grafts. (PubMed, Int J Mol Sci) - "PCmAb effectively inhibits murine atherosclerotic lesion formation in vein grafts by reducing IPA and IPH via decreased neovessel density and macrophages influx and increased neovessel maturation. PC-mAb therefore holds promise as a new therapeutic approach to prevent vein graft disease."

Journal • Preclinical • Atherosclerosis • Cardiovascular • Dyslipidemia • Hematological Disorders • CD163

Phosphorylcholine antibodies restrict infarct size and left ventricular remodelling by attenuating the unreperfused post-ischaemic inflammatory response. (PubMed, J Cell Mol Med) - "In conclusion, the local and systemic inflammatory responses are limited by PC-mAb treatment resulting in restricted adverse cardiac remodelling and IS following unreperfused MI. This indicates that PC-mAb holds promise as a therapeutic agent following MI limiting adverse cardiac remodelling."

Journal • Cardiovascular • Immunology • Inflammation • Myocardial Infarction • Systemic Inflammatory Response Syndrome • APOE • CCL2

Efficacy, Safety and Tolerability of ATH3G10 in Patients With ST-elevation Myocardial Infarction (clinicaltrials.gov) - P2a; N=82; Completed; Sponsor: Athera Biotechnologies AB; Active, not recruiting ➔ Completed

Clinical • Trial completion • Cardiovascular • Myocardial Infarction

Circulating oxidized LDL, increased in patients with acute myocardial infarction, is accompanied by heavily modified HDL. (PubMed, J Lipid Res) - "The electronegative in vivo-oxLDL was immunologically purified from the LDL(-) fraction with an anti-oxPC mAb. The majority of PC species were not oxidized, whereas oxPC and lysoPC did not accumulate. Here, we propose that there are two types of in vivo-oxLDL in human circulating plasma and the electronegative in vivo-oxLDL accompanies oxidized HDL."

Clinical • Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Immunology • Myocardial Infarction • APOA1 • APOB

Phosphorylcholine Antibodies Preserve Cardiac Function and Reduce Infarct Size by Attenuating the Post-Ischemic Inflammatory Response. (PubMed, JACC Basic Transl Sci) - "This subsequently enhances the post-ischemic repair process, resulting in limited adverse cardiac remodeling and preservation of cardiac function. Therefore, phosphorylcholine monoclonal immunoglobulin G antibody therapy may be a valid therapeutic approach against myocardial ischemia-reperfusion injury."

Journal • Cardiovascular • Immunology • Inflammation • Myocardial Infarction • Myocardial Ischemia • Reperfusion Injury • CCL2

Identification of IgG1 isotype phosphorylcholine antibodies for the treatment of inflammatory cardiovascular diseases. (PubMed, J Intern Med) - "IN chimeric anti-PCs can prevent accelerated atherosclerosis by inhibiting vascular inflammation directly and through reduced macrophage oxLDL-uptake resulting in decreased lesions. PC-mAb represents a novel strategy for cardiovascular disease prevention."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Immunology • Inflammation • CCL2

A core fucose-deficient anti-podocalyxin antibody exhibits antitumor activity via augmented antibody-dependent cellular cytotoxicity in oral squamous cell carcinoma (AACR 2018) - "...We recently produced sensitive and specific anti-podocalyxin mAb PcMab-47, which reacts with endogenous podocalyxin-expressing cancer cell lines... A core fucose-deficient anti-podocalyxin mAb could be useful for antibody-based therapy against podocalyxin-expressing OSCCs."

IO Biomarker • Colorectal Cancer • Oral Cancer

A cancer-specific anti-podocalyxin monoclonal antibody (60-mG-f) exerts antitumor effects in mouse xenograft models of pancreatic carcinoma. (PubMed, Biochem Biophys Rep) - "In this study, we developed an anti-PODXL cancer-specific mAb (CasMab), named as PcMab-60 (IgM, kappa) by immunizing mice with soluble PODXL, which is overexpressed in LN229 glioblastoma cells...In vivo analysis revealed that 60-mG-f exerted antitumor activity in MIA PaCa-2 xenograft models at a dose of 100 μg/mouse/week administered three times. These results suggested that 60-mG-f could be useful for antibody-based therapy against PODXL-expressing pancreatic cancers."

Journal • Preclinical • Gastrointestinal Cancer • Glioblastoma • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • PODXL

Identification of novel monoclonal antibodies targeting the outer membrane protein C and lipopolysaccharides for Escherichia coli O157:H7 detection. (PubMed, J Appl Microbiol) - "ECO157 specific detection was improved by a combination of the novel OmpC mAb and LPS mAb with defined target antigen and good specificity."

Journal

[VIRTUAL] IgG1 phosphorylcholine ameliorates plaque stability via reduced intraplaque angiogenesis and intraplaque haemorrhage in a murine atherosclerosis model (ESC 2020) - "PCmAB is an effective inhibitor of atherosclerotic lesion formation in ApoE3*Leiden mice. PCmAb reduces IPA and IPH by decreased neovessel density and (CD163+) macrophages influx via reduced expression of VCAM-1 and ICAM-1, and increased neovessel maturation in vein graft atherosclerosis. PCmAB holds a promise as a new therapeutic approach for plaque stability."

Preclinical • Atherosclerosis • Cardiovascular • Dyslipidemia • CD 163 • HP • ICAM1 • VCAM1 • VEGFA

Efficacy, Safety and Tolerability of ATH3G10 in Patients With ST-elevation Myocardial Infarction (clinicaltrials.gov) - P2a; N=82; Active, not recruiting; Sponsor: Athera Biotechnologies AB; Recruiting ➔ Active, not recruiting; Trial completion date: Nov 2020 ➔ Mar 2021; Trial primary completion date: Mar 2020 ➔ Jul 2020

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • Myocardial Infarction

Immunohistochemical Analysis Using Antipodocalyxin Monoclonal Antibody PcMab-47 Demonstrates Podocalyxin Expression in Oral Squamous Cell Carcinomas. (PubMed, Monoclon Antib Immunodiagn Immunother) - "PcMab-47-stained oral squamous cell carcinoma cells in a cytoplasmic pattern and detected 26/38 (68.4%) of oral squamous cell carcinoma cells on tissue microarrays. These results indicate that PcMab-47 is useful in detecting podocalyxin of oral cancers for immunohistochemical analysis."

Journal • Biosimilar • Breast Cancer • Colorectal Cancer • Ophthalmology • Oral Cancer

Anti-podocalyxin cancer-specific monoclonal antibody: preclinical study (AACR 2017) - "ChPcMab-6, a cancer-specific human-mouse chimeric anti-podocalyxin mAb could be useful for targeting podocalyxin in cancer, although podocalyxin is highly expressed in many normal cells."

Biosimilar • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Mesothelioma • Oncology • Pancreatic Cancer

Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates Vascular F-FDG Uptake in Atherosclerotic Mice. (PubMed, JACC Basic Transl Sci) - "This study showed that treatment with a therapeutic monoclonal immunoglobulin-G1 antibody against phosphorylcholine on oxidized phospholipids preserves coronary flow reserve and attenuates atherosclerotic inflammation as determined by the uptake of F-fluorodeoxyglucose in atherosclerotic mice. The noninvasive imaging techniques represent translational tools to assess the efficacy of phosphorylcholine-targeted therapy on coronary artery function and atherosclerosis in clinical studies."

Journal • Preclinical

Targeted photoimmunotherapy based on photosensitizer-antibody conjugates for multiple myeloma treatment. (PubMed, J Photochem Photobiol B) - "The radioactivated photoimmuno-conjugates I(PcMAb) demonstrated the highest phototoxicity to myeloma cells. The suggested bioconjugates are promising candidates as multiple therapeutic models for in vivo treatment of myeloma."

Journal

Efficacy, Safety and Tolerability of ATH3G10 in Patients With ST-elevation Myocardial Infarction (clinicaltrials.gov) - P2a; N=80; Recruiting; Sponsor: Athera Biotechnologies AB

Clinical • New P2a trial

Toward biotherapeutic product real-time quality monitoring. (PubMed, Crit Rev Biotechnol) - "Recent analytical techniques used for assessment of product-related CQAs of mAbs are considered in light of the analytical speed and ability to measure different CQAs. Furthermore, the state of art modeling approaches for CQA estimation in real-time are presented as a viable alternative for real-time bioproduct CQA monitoring under the process analytical technology and quality-by-design frameworks in the biopharmaceutical industry, which have recently been demonstrated."

Journal